Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 31 entries
Sorted by: Best Match Show Resources per page
Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K.
PMID: 25088236
Hepatol Res. 2015 Jun;45(6):656-62. doi: 10.1111/hepr.12400. Epub 2014 Sep 02.

AIM: To assess the efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis (PVT) in patients with liver cirrhosis.METHODS: A consecutive 26 cirrhotic patients with PVT were enrolled in this retrospective cohort...

Cite
Naeshiro N, Aikata H, Hyogo H, et al. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2014;45(6):656-62doi: 10.1111/hepr.12400.
Naeshiro, N., Aikata, H., Hyogo, H., Kan, H., Fujino, H., Kobayashi, T., Fukuhara, T., Honda, Y., Nakahara, T., Ohno, A., Miyaki, D., Murakami, E., Kawaoka, T., Tsuge, M., Hiraga, N., Hiramatsu, A., Imamura, M., Kawakami, Y., Ochi, H., & Chayama, K. (2015). Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology, 45(6), 656-62. https://doi.org/10.1111/hepr.12400
Naeshiro, Noriaki, et al. "Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 45,6 (2015): 656-62. doi: https://doi.org/10.1111/hepr.12400
Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2015 Jun;45(6):656-62. doi: 10.1111/hepr.12400. Epub 2014 Sep 02. PMID: 25088236.
Copy Download .nbib Format: NLM
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Vakil NH, Kanaan AO, Donovan JL.
PMID: 23118656
J Pediatr Pharmacol Ther. 2012 Jan;17(1):12-30. doi: 10.5863/1551-6776-17.1.12.

Heparin-induced thrombocytopenia is a rare and serious reaction to unfractionated heparin and low-molecular-weight heparins in children. Quick recognition, discontinuation of heparin, and subsequent treatment with an alternative anticoagulant are essential steps to prevent serious complications such as thrombus and...

Cite
Vakil NH, Kanaan AO, Donovan JL. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther. 2012;17(1):12-30doi: 10.5863/1551-6776-17.1.12.
Vakil, N. H., Kanaan, A. O., & Donovan, J. L. (2012). Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 17(1), 12-30. https://doi.org/10.5863/1551-6776-17.1.12
Vakil, Niyati H, et al. "Heparin-induced thrombocytopenia in the pediatric population: a review of current literature." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 17,1 (2012): 12-30. doi: https://doi.org/10.5863/1551-6776-17.1.12
Vakil NH, Kanaan AO, Donovan JL. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther. 2012 Jan;17(1):12-30. doi: 10.5863/1551-6776-17.1.12. PMID: 23118656; PMCID: PMC3428184.
Copy Download .nbib Format: NLM
The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?.

Research and practice in thrombosis and haemostasis

De Kesel PMM, Devreese KMJ.
PMID: 31989098
Res Pract Thromb Haemost. 2019 Dec 10;4(1):161-168. doi: 10.1002/rth2.12264. eCollection 2020 Jan.

BACKGROUND: Heparins and heparinoids interfere with functional clotting assays used for lupus anticoagulant (LAC) detection. However, current guidelines for LAC testing do not provide clear guidance on this matter.OBJECTIVES: We aimed to assess to effect of unfractionated heparin (UFH),...

Cite
De Kesel PMM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?. Res Pract Thromb Haemost. 2019;4(1):161-168doi: 10.1002/rth2.12264.
De Kesel, P. M. M., & Devreese, K. M. J. (2020). The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?. Research and practice in thrombosis and haemostasis, 4(1), 161-168. https://doi.org/10.1002/rth2.12264
De Kesel, Pieter M M, and Devreese, Katrien M J. "The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?." Research and practice in thrombosis and haemostasis vol. 4,1 (2020): 161-168. doi: https://doi.org/10.1002/rth2.12264
De Kesel PMM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?. Res Pract Thromb Haemost. 2019 Dec 10;4(1):161-168. doi: 10.1002/rth2.12264. eCollection 2020 Jan. PMID: 31989098; PMCID: PMC6971310.
Copy Download .nbib Format: NLM
Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report.

Molecular and clinical oncology

Yagi T, Nakamura H, Wakamatsu T, Imura Y, Tamiya H, Sabe H, Yamashita K, Watanabe M, Takenaka S.
PMID: 33815793
Mol Clin Oncol. 2021 May;14(5):104. doi: 10.3892/mco.2021.2266. Epub 2021 Mar 17.

Angiosarcoma is a rare sarcoma with a poor prognosis and is prone to disseminated intravascular coagulation (DIC), where DIC often interferes with chemotherapy. Primary angiosarcoma of the breast (PASB) is a type of angiosarcoma that is located in mammary...

Cite
Yagi T, Nakamura H, Wakamatsu T, et al. Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report. Mol Clin Oncol. 2021;14(5):104doi: 10.3892/mco.2021.2266.
Yagi, T., Nakamura, H., Wakamatsu, T., Imura, Y., Tamiya, H., Sabe, H., Yamashita, K., Watanabe, M., & Takenaka, S. (2021). Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report. Molecular and clinical oncology, 14(5), 104. https://doi.org/10.3892/mco.2021.2266
Yagi, Toshinari, et al. "Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report." Molecular and clinical oncology vol. 14,5 (2021): 104. doi: https://doi.org/10.3892/mco.2021.2266
Yagi T, Nakamura H, Wakamatsu T, Imura Y, Tamiya H, Sabe H, Yamashita K, Watanabe M, Takenaka S. Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report. Mol Clin Oncol. 2021 May;14(5):104. doi: 10.3892/mco.2021.2266. Epub 2021 Mar 17. PMID: 33815793; PMCID: PMC8010513.
Copy Download .nbib Format: NLM
Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature.

Sultan Qaboos University medical journal

Alkindi S, Smith OP, Enright H.
PMID: 22087382
Sultan Qaboos Univ Med J. 2011 Aug;11(3):391-8. Epub 2011 Aug 15.

Heparin is one of the most frequently used anticoagulants. It is easy to use, but can be associated with life-threatening side effects. One of these is heparin-induced thrombocytopenia syndrome (HITS), which develops in about 3-5% of patients exposed to...

Cite
Alkindi S, Smith OP, Enright H. Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature. Sultan Qaboos Univ Med J. 2011;11(3):391-8
Alkindi, S., Smith, O. P., & Enright, H. (2011). Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature. Sultan Qaboos University medical journal, 11(3), 391-8.
Alkindi, Salam, et al. "Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature." Sultan Qaboos University medical journal vol. 11,3 (2011): 391-8.
Alkindi S, Smith OP, Enright H. Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature. Sultan Qaboos Univ Med J. 2011 Aug;11(3):391-8. Epub 2011 Aug 15. PMID: 22087382; PMCID: PMC3210050.
Copy Download .nbib Format: NLM
Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report.

Neurology

Walter U, Fuchs M, Grossmann A, Walter M, Thiele T, Storch A, Wittstock M.
PMID: 34312301
Neurology. 2021 Jul 26; doi: 10.1212/WNL.0000000000012576. Epub 2021 Jul 26.

OBJECTIVE: Venous thromboses and thrombocytopenia after vaccination with the adenovirus-vectored COVID-19 vaccine ChAdOx1 nCov-19 (AstraZeneca) have been linked to serum antibodies against platelet factor 4 (PF4)-polyanion complexes. We here report vaccine-induced isolated carotid arterial thrombosis.METHODS: Imaging and laboratory findings,...

Cite
Walter U, Fuchs M, Grossmann A, et al. Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report. Neurology. 2021;doi: 10.1212/WNL.0000000000012576.
Walter, U., Fuchs, M., Grossmann, A., Walter, M., Thiele, T., Storch, A., & Wittstock, M. (2021). Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report. Neurology, . https://doi.org/10.1212/WNL.0000000000012576
Walter, Uwe, et al. "Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report." Neurology vol. (2021). doi: https://doi.org/10.1212/WNL.0000000000012576
Walter U, Fuchs M, Grossmann A, Walter M, Thiele T, Storch A, Wittstock M. Adenovirus-Vectored COVID-19 Vaccine-Induced Immune Thrombosis of Carotid Artery: A Case Report. Neurology. 2021 Jul 26; doi: 10.1212/WNL.0000000000012576. Epub 2021 Jul 26. PMID: 34312301.
Copy Download .nbib Format: NLM
Aortocoronary Vein Bypass in a Patient with Type II Heparin-Associated Thrombopenia: A Case Report.

The International journal of angiology : official publication of the International College of Angiology, Inc

Christiansen S, Geiger A, Splittgerber FH, Reidemeister JC.
PMID: 9585467
Int J Angiol. 1998 May;7(3):268-70. doi: 10.1007/BF01617410.

Two types of heparin-associated thrombopenia (HAT) can be distinguished. Patients with type II HAT (HAT II) present a particularly difficult management problem when they require full anticoagulation. There is no consensus about the proper anticoagulation management for patients with...

Cite
Christiansen S, Geiger A, Splittgerber FH, et al. Aortocoronary Vein Bypass in a Patient with Type II Heparin-Associated Thrombopenia: A Case Report. Int J Angiol. 1998;7(3):268-70doi: 10.1007/BF01617410.
Christiansen, S., Geiger, A., Splittgerber, F. H., & Reidemeister, J. C. (1998). Aortocoronary Vein Bypass in a Patient with Type II Heparin-Associated Thrombopenia: A Case Report. The International journal of angiology : official publication of the International College of Angiology, Inc, 7(3), 268-70. https://doi.org/10.1007/BF01617410
Christiansen, et al. "Aortocoronary Vein Bypass in a Patient with Type II Heparin-Associated Thrombopenia: A Case Report." The International journal of angiology : official publication of the International College of Angiology, Inc vol. 7,3 (1998): 268-70. doi: https://doi.org/10.1007/BF01617410
Christiansen S, Geiger A, Splittgerber FH, Reidemeister JC. Aortocoronary Vein Bypass in a Patient with Type II Heparin-Associated Thrombopenia: A Case Report. Int J Angiol. 1998 May;7(3):268-70. doi: 10.1007/BF01617410. PMID: 9585467.
Copy Download .nbib Format: NLM
Heparin-induced Thrombocytopenia.

Current treatment options in cardiovascular medicine

Gerhard-Herman M.
PMID: 11341867
Curr Treat Options Cardiovasc Med. 2001 Jun;3(3):215-224. doi: 10.1007/s11936-001-0040-7.

Treatment with heparin is associated with two types of thrombocytopenia. The most worrisome of these is the immune-mediated heparin-induced thrombocytopenia (HIT type II). Suspicion of HIT type II mandates immediate cessation of heparin administration and consideration of an alternative...

Cite
Gerhard-Herman M. Heparin-induced Thrombocytopenia. Curr Treat Options Cardiovasc Med. 2001;3(3):215-224doi: 10.1007/s11936-001-0040-7.
Gerhard-Herman, M. (2001). Heparin-induced Thrombocytopenia. Current treatment options in cardiovascular medicine, 3(3), 215-224. https://doi.org/10.1007/s11936-001-0040-7
Gerhard-Herman, Marie. "Heparin-induced Thrombocytopenia." Current treatment options in cardiovascular medicine vol. 3,3 (2001): 215-224. doi: https://doi.org/10.1007/s11936-001-0040-7
Gerhard-Herman M. Heparin-induced Thrombocytopenia. Curr Treat Options Cardiovasc Med. 2001 Jun;3(3):215-224. doi: 10.1007/s11936-001-0040-7. PMID: 11341867.
Copy Download .nbib Format: NLM
Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome.

Reproductive medicine and biology

Shimada S, Yamada H, Atsumi T, Yamada T, Sakuragi N, Minakami H.
PMID: 29699347
Reprod Med Biol. 2010 Jun 15;9(4):217-221. doi: 10.1007/s12522-010-0056-3. eCollection 2010 Dec.

We encountered a woman who had a history of repeated fetal losses and positive tests for lupus anticoagulant, phosphatidylserine-dependent antiprothrombin (aPS/PT) IgG, IgM and kininogen-dependent antiphosphatidylethanolamine (aPE) IgG, IgM. Her previous pregnancy had ended in intrauterine fetal death at...

Cite
Shimada S, Yamada H, Atsumi T, et al. Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome. Reprod Med Biol. 2010;9(4):217-221doi: 10.1007/s12522-010-0056-3.
Shimada, S., Yamada, H., Atsumi, T., Yamada, T., Sakuragi, N., & Minakami, H. (2010). Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome. Reproductive medicine and biology, 9(4), 217-221. https://doi.org/10.1007/s12522-010-0056-3
Shimada, Shigeki, et al. "Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome." Reproductive medicine and biology vol. 9,4 (2010): 217-221. doi: https://doi.org/10.1007/s12522-010-0056-3
Shimada S, Yamada H, Atsumi T, Yamada T, Sakuragi N, Minakami H. Intravenous immunoglobulin therapy for aspirin-heparinoid-resistant antiphospholipid syndrome. Reprod Med Biol. 2010 Jun 15;9(4):217-221. doi: 10.1007/s12522-010-0056-3. eCollection 2010 Dec. PMID: 29699347; PMCID: PMC5904649.
Copy Download .nbib Format: NLM
Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Lubenow N, Greinacher A.
PMID: 18034563
BioDrugs. 2000 Aug;14(2):109-25. doi: 10.2165/00063030-200014020-00005.

Recombinant hirudins have a definite role in the treatment of patients with heparin-induced thrombocytopenia (HIT). The most important adverse effects are haemorrhages and the induction of antihirudin antibodies. Major haemorrhages were not significantly increased in patients with HIT compared...

Cite
Lubenow N, Greinacher A. Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs. 2000;14(2):109-25doi: 10.2165/00063030-200014020-00005.
Lubenow, N., & Greinacher, A. (2000). Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 14(2), 109-25. https://doi.org/10.2165/00063030-200014020-00005
Lubenow, N, and Greinacher, A. "Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 14,2 (2000): 109-25. doi: https://doi.org/10.2165/00063030-200014020-00005
Lubenow N, Greinacher A. Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin. BioDrugs. 2000 Aug;14(2):109-25. doi: 10.2165/00063030-200014020-00005. PMID: 18034563.
Copy Download .nbib Format: NLM
[Heparin-induced thrombocytopenia: Update].

La Revue de medecine interne

Camoin-Jau L, Mariotti A, Suchon P, Morange PE.
PMID: 34535328
Rev Med Interne. 2021 Sep 14; doi: 10.1016/j.revmed.2021.08.011. Epub 2021 Sep 14.

Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy. It is due to the synthesis of antibodies most often directed against platelet factor 4 (FP4) modified by heparin (H). HIT is manifested by a platelet count fall, associated...

Cite
Camoin-Jau L, Mariotti A, Suchon P, et al. La thrombopénie induite par héparine : mise au point. [Heparin-induced thrombocytopenia: Update]. Rev Med Interne. 2021;doi: 10.1016/j.revmed.2021.08.011.
Camoin-Jau, L., Mariotti, A., Suchon, P., & Morange, P. E. (2021). La thrombopénie induite par héparine : mise au point. [Heparin-induced thrombocytopenia: Update]. La Revue de medecine interne, . https://doi.org/10.1016/j.revmed.2021.08.011
Camoin-Jau, L, et al. "La thrombopénie induite par héparine : mise au point." [Heparin-induced thrombocytopenia: Update]. La Revue de medecine interne vol. (2021). doi: https://doi.org/10.1016/j.revmed.2021.08.011
Camoin-Jau L, Mariotti A, Suchon P, Morange PE. La thrombopénie induite par héparine : mise au point. [Heparin-induced thrombocytopenia: Update]. Rev Med Interne. 2021 Sep 14; doi: 10.1016/j.revmed.2021.08.011. Epub 2021 Sep 14. French. PMID: 34535328.
Copy Download .nbib Format: NLM
Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US.

Infection

Rodriguez EVC, Bouazza FZ, Dauby N, Mullier F, d'Otreppe S, Jissendi Tchofo P, Bartiaux M, Sirjacques C, Roman A, Hermans C, Cliquennois M.
PMID: 34626338
Infection. 2021 Oct 09; doi: 10.1007/s15010-021-01712-8. Epub 2021 Oct 09.

PURPOSE: We reported the first described post Ad26.COV2.S (Janssen, Johnson & Johnson) vaccine-induced immune thrombocytopenia (VITT) case outside US.  CASE DESCRIPTION: CA young woman without any medical history presented association of deep vein thrombosis and thrombocytopenia at day 10...

Cite
Rodriguez EVC, Bouazza FZ, Dauby N, et al. Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US. Infection. 2021;doi: 10.1007/s15010-021-01712-8.
Rodriguez, E. V. C., Bouazza, F. Z., Dauby, N., Mullier, F., d'Otreppe, S., Jissendi Tchofo, P., Bartiaux, M., Sirjacques, C., Roman, A., Hermans, C., & Cliquennois, M. (2021). Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US. Infection, . https://doi.org/10.1007/s15010-021-01712-8
Rodriguez, Elsa V C, et al. "Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US." Infection vol. (2021). doi: https://doi.org/10.1007/s15010-021-01712-8
Rodriguez EVC, Bouazza FZ, Dauby N, Mullier F, d'Otreppe S, Jissendi Tchofo P, Bartiaux M, Sirjacques C, Roman A, Hermans C, Cliquennois M. Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US. Infection. 2021 Oct 09; doi: 10.1007/s15010-021-01712-8. Epub 2021 Oct 09. PMID: 34626338; PMCID: PMC8501343.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 31 entries